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CORRESPONDENCE Open Access
T cells fail to develop in the human skin-cell
explants system; an inconvenient truth
Bob Meek1, Catharina HMJ Van Elssen1,2, Mirelle JAJ Huijskens1, Sjoukje JC van der Stegen1, Siebe Tonnaer2,
Stijn BJ Lumeij2, Joris Vanderlocht1, Mark A Kirkland3, Reinout Hesselink2, Wilfred TV Germeraad1*, Gerard MJ Bos1
Abstract
Background: Haplo-identical hematopoietic stem cell (HSC) transplantation is very successful in eradicating
haematological tumours, but the long post-transplant T-lymphopenic phase is responsible for high morbidity and
mortality rates. Clark et al. have described a skin-explant system capable of producing host-tolerant donor-HSC
derived T-cells. Because this T-cell production platform has the potential to replenish the T-cell levels following
transplantation, we set out to validate the skin-explant system.
Results: Following the published procedures, while using the same commercial components, it was impossible to
reproduce the skin-explant conditions required for HSC differentiation towards mature T-cells. The keratinocyte
maturation procedure resulted in fragile cells with minimum expression of delta-like ligand (DLL). In most
experiments the generated cells failed to adhere to carriers or were quickly outcompeted by fibroblasts.
Consequently it was not possible to reproduce cell-culture conditions required for HSC differentiation into
functional T-cells. Using cell-lines over-expressing DLL, we showed that the antibodies used by Clark et al. were
unable to detect native DLL, but instead stained 7AAD+ cells. Therefore, it is unlikely that the observed T-lineage
commitment from HSC is mediated by DLL expressed on keratinocytes. In addition, we did confirm expression of
the Notch-ligand Jagged-1 by keratinocytes.
Conclusions: Currently, and unfortunately, it remains difficult to explain the development or growth of T-cells
described by Clark et al., but for the fate of patients suffering from lymphopenia it is essential to both reproduce
and understand how these co-cultures really “work”. Fortunately, alternative procedures to speed-up T-cell
reconstitution are being established and validated and may become available for patients in the near future.
Background
Lymphopenia results in high mortality and morbidity
among cancer patients receiving a hematopoietic stem
cell (HSC) transplantation, or suffering from HIV infec-
tion [1-5]. Eradication of hematological cancers is very
successful using haplo-identical HSC transplantation [6],
but many patients succumb to opportunistic infections
that are the direct consequence of the lymphopenia,
mainly involving the T cell pool [7]; it often takes more
than 200 days before (mainly CD4+) T cell levels have
normalized again. This underlines the need for, and
explains the general interest in, methods capable of
enhancing T cell reconstitution [8,9].
Two important problems associated with slow recov-
ery of T cell levels involve the thymus: slow thymic
reconstitution by blood-borne progenitors and thymic
involution [10-14]. Because it is still not possible to con-
trol and/or reverse either of these processes, there is an
obvious need to establish methods that generate a de
novo T cell repertoire in vitro. However, the develop-
ment of such systems is hampered because most
processes that occur in the thymus are still enigmatic,
especially how the thymus is capable to enforce self ver-
sus non-self recognition on developing thymocytes [15].
Understanding the process of positive/negative selection,
and reproducing the process in vitro, would potentially
help to reduce lymphopenia, especially in older patients
as the thymus involutes with age. In this context, the
results on thymus-independent T cell development pre-
viously described by Clark et al. are remarkable. This
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method involves a seemingly simple co-culture system
consisting of skin keratinocytes and fibroblasts grown
on a three-dimensional (3D) tantalum covered scaffold
(Statamatrix®) that, after 4 weeks co-culture with allo-
genic HSC, results in a population containing 3-5% T
cells tolerant to the skin-donor [16]. Even though T
cells were detected, only a limited fraction of the
expanded HSC actually became T-lineage committed;
many cells differentiated towards Class II+ APC, a con-
venient aspect since it was suggested to be important
for CD4+ T cell development [16]. Additional explana-
tions for the extra-thymic development of T cells were
the co-incidental expression of various components
known to be important for HSC differentiation and thy-
mus-function, such as Delta-Like Ligand (DLL) [8] and
AutoImmune Regulator (AIRE) [17] by keratinocytes
and fibroblasts [16], respectively.
Even though direct mechanistic explanations for the
extra-thymic development of T cells are lacking, and
despite limited numbers, it still remains the only pub-
lished method potentially capable of generating func-
tional, clinical-grade, mature T cells ex vivo. Because
of the clinical importance, we made an effort to estab-
lish the skin-cell system in our laboratory and to char-
acterize it in more detail. We observed that
keratinocytes do express the Notch ligand Jagged1, but
we did not find the abundant expression of DLL pro-
tein previously reported by Clark et al. on keratino-
cytes. Furthermore, due to the growth characteristics
of keratinocytes and fibroblasts in the Statamatrix®, we
could not reproduce the co-cultures as described by
Clark et al. [16]. As a result, we never observed any
T-lineage differentiation. The various reasons for the
unsuccessful reproduction of this method are described
in this report.
Results
The in vitro T cell development from donor CD34+ cells
as described by Clark et al. [16] requires a co-culture of
(recipient = patient) keratinocytes and fibroblasts. To
confirm expression of determinants reported to be
important for in vitro differentiation, and establish co-
cultures, we prepared keratinocyte and fibroblast cell
banks from various donors and different skin sources.
Sufficient numbers of early passage stocks were available
from 5 donors for all experiments.
Is DLL expressed by keratinocytes?
Many papers have described the necessity for Notch sig-
naling in T cell determination and differentiation from
CD34+ cells (reviewed in [8]). One of the most obvious
and logical explanations provided by Clark et al. [16] for
the generation of T cells was the innate potential of
matured keratinocytes to express DLL protein. To
detect/confirm DLL expression on intact keratinocytes,
we used three different methods.
FACS analysis
In the paper by Clark et al. [16], it was not specified at
what stage the keratinocytes were harvested, and which
DLL was detected by the polyclonal H265 antibody. In
our hands, the differentiation procedure resulted in a
mixture of undifferentiated and early-differentiated
cells; none of the “differentiated” keratinocytes ever
lost CK14 expression, which is a marker for mature
keratinocytes (Figure 1). By using murine cell-lines
(genetically) over-expressing human DLL1 or 4 it
became clear that the H265 antibody used for FACS
and IF does recognize DLL1, but not DLL4 (Figure
2A). Using a murine stromal cell line transduced with
human DLL1 as positive control, which shows intense
staining of DLL1 on immunoblot (Figure 2A), we
found that it was possible to detect DLL1 on vital cells
by flowcytometry (FACS), albeit with difficulty (Figure
2B). When matured keratinocytes were indirectly
stained with H265 for analysis by FACS, we were
never able to detect a specific signal from H265 on
vital, 7AAD- keratinocytes (Figure 3A). Other primary
rabbit antibodies specific for intracellular antigens,
normally not expressed by keratinocytes like NOS2
and IRF1, also stained 7AAD- keratinocytes (Figure
3A), indicating that these antibody-preparations may
not be suitable for analysis by FACS. We did find that
7AAD+/DAPI+ cells were intensely stained by all pri-
mary rabbit antibodies, including H265 (Figure 3B),
generating a false positive H265/SSC picture very simi-
lar as published by Clark et al. [16]. Apparently, it is
possible to use the FACS procedure in combination
with H265 to detect DLL1 expression on the surface of
DLL1-transfected cell-lines, but it cannot be used to
reliably stain DLL on vital keratinocytes.
Another question that arose was whether H265 is
suitable for detection of intact DLL. Because the anti-
body was generated against a peptide spanning the
membrane and the first twenty amino-acids of the extra-
cellular domain, it may recognize processed DLL only
(the epitope could be shielded by the 3D folding of the
protein), thereby under-representing the actual level of
DLL surface-expression. Therefore, using a goat-polyclo-
nal antibody capable of binding to a known, accessible
epitope in the extracellular domain of DLL1, H20, we
repeated the experiments with DLL-transduced cells
(Figure 2A and 2B) and keratinocytes (Figure 3C), but
no specific staining on intact keratinocytes was detected.
When considering the weak specific signals obtained
with either H20 or H265 on cell-lines over-expressing
DLL, it is obvious to conclude that it is impossible to
demonstrate spontaneous DLL expression on intact pri-
mary cells with these antibodies.
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Figure 2 Analyses of DLL expression by Immunoblot and FACS using cell-lines over-expressing DLL. (A) Protein blots were prepared
from TSt-4 thymic stromal cell-lines over-expressing human DLL1 or 4, and incubated with polyclonal antibodies specific for DLL. Both H20 and
H265 only stained lanes containing TSt-4-DLL1 extracts, with a main band at 78 kDa. H265 stained additional bands at 50 kDa and 230 kDa,
which could represent processed and glycosylated DLL-1, respectively. In contrast to H20, H265 also heavily stained the marker-lane, indicating
that the specificity of this polyclonal antibody preparation is not limited to DLL. (B) Indicated cells were harvested using trypsin-EDTA, and
incubated with H265 and H20 + control polyclonal antibodies specific for IRF1 and ACE. Control antibodies were selected based on species-
origin and specificity for non-surface antigens. Both H265 and H20 showed weak, yet specific staining of TSt4-DLL1.
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Figure 1 Differentiation of keratinocytes results in a mixture of immature and semi mature cells. Keratinocytes of a representative donor
were differentiated in chamber-slides for 6 days. Following fixation, cells were stained for the indicated cytokeratins (CK) using a panel of
monoclonal (CK10, CK14, CK16) and polyclonal antibodies (pan). Duration of fluorescence detection was kept constant. Though variable, all cells
were positive for CK14, while staining of CK10 and CK16 was limited to areas with blast-like keratinocytes.
Meek et al. BMC Immunology 2011, 12:17
http://www.biomedcentral.com/1471-2172/12/17
Page 3 of 13
Immunofluorescence
To confirm DLL expression by FACS, Clark et al. [16]
used immunofluorescence on fixed keratinocytes pre-
pared by cytospin, which is an application reported sui-
table for both H265 and H20. However, again no
detection of any DLL staining of intact, differentiated
keratinocytes was observed; the occasional green cell we
did see (resembling Figure Five C in [16]) proved to
have no nucleus (Figure 4A). In contrast, keratinocytes
did stain positive for Notch ligand Jagged-1 (Figure 4A).
PCR
Since it was not possible to reliably detect DLL1 or
DLL4 protein, we reverted to PCR to find out whether
matured keratinocytes are at least capable to express
high level of DLL RNA. As shown in Figure 4B, com-
pared with gene-products normally expressed by kerati-
nocytes, cDNA encoding for DLL4 required 35 cycles
before detection. Clearly, expression of DLL is far from
abundant in differentiated or immature keratinocytes
(Figure 4B). In contrast to DLL expression, the high
level of Jagged-1 expression was confirmed by detecting
PCR products after 30 cycles (Figure 4B). This observa-
tion is in line with a previous report demonstrating high
levels of Jagged-1 expression at various stages of kerati-
nocyte-development [18].
In summary, using three different methods we could
not detect any DLL expression by keratinocytes, which
makes it unlikely that HSC differentiation towards
T lineage as observed by Clark et al. [16] is initiated by
T-lineage commitment induced by DLL expressed on
keratinocytes. Of course, we do not know whether (or
why) keratinocytes start to express DLL during co-
culture with fibroblasts, or whether DLL-expression by
keratinocytes is actually required for the extra-thymic
T cell development. On the other hand, keratinocytes
do show abundant expression of Jagged-1. Even though
Jagged-1 by itself is not particularly efficient in induc-
tion of T-lineage differentiation of cord blood derived
CD34+ cells [19], and its expression in the murine thy-
mus is not abundant [20,21], Jagged-1-mediated activa-
tion of murine thymic precursors does result in T/NK
progenitors [20]. Therefore, it cannot be excluded that
Jagged-1 does so as well in the context of the skin
explants system.
A balanced co-culture?
The system requires co-culture of keratinocytes and fibro-
blasts on the Statamatrix®. However, “matured” keratino-
cytes showed limited capacity to adhere to collagen-coated
Statamatrices®, in contrast to fibroblasts, and these latter
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Figure 3 7AAD+ Keratinocytes show intense staining with any polyclonal primary antibody. Keratinocytes of donor C were harvested
following high-density culture for 6 days, either in standard keratinocyte (iKer) or maturation medium (dKer). (A) All cells being stained with
indicated rabbit pan antibodies were 7AAD+. Left column shows FACS plots as used by Clark et al. [15], right column contains additional
information regarding viability. Within experiments, the percentage of positively stained cells was always similar with any pan-antibody. Insert
shows background staining by the secondary antibody used. Even though staining intensity was lower after incubation with the secondary
antibody, when compared with unstained cells (LL quadrant of the right column), the percentage of cells with signal was similar. This staining-
pattern was observed for all donors. (B) When gated on 7AAD- cells, any pan antibody stained a low percentage of keratinocytes (donor C,
donor D showed similar inconclusive staining profile). (C) Almost all cells that were stained with H265, co-stained with H20. A nearly similar plot
could be obtained with any pan rabbit (eg ACE) and pan goat antibody combination (eg, NOS2), and invariably involved 7AAD+ cells (donor C,
donor D showed similar co-staining).
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cells always overgrew in keratinocyte-fibroblast co-cultures
in matrices within 7 days (Figure 5A and 5B).
Skin explant procedure did not result in T lineage-
development
We found that HSC (expressing either CD34+ or AC133 +)
were never able to differentiate towards T-lineage cells in
matrices containing isolated and cultured fibroblasts and
keratinocytes; most HSC did up-regulate CD7 and lost the
CD34 marker, but no expression of early T-lineage
markers like CD5 (Figure 6), nor the CD56 NK cell mar-
ker were observed (data not shown). In contrast, the same
batches of HSC demonstrated excellent T lineage differen-
tiation capacity when grown on murine stromal cell lines
expressing human DLL [22].
DLL-independent development?
As indicated, the phenotype of the differentiated HSC
suggested lack of Notch signaling, which could be due
to the lowered keratinocyte/fibroblast ratio. Since it
seems very difficult to alter that ratio with the published
protocol, it may be difficult to routinely use the skin
explants procedure. However, the explants system
remains unique in the fact that it encompasses complete
T cell development resulting in functional, single-posi-
tive CD4 and CD8 T cells, which includes the poorly
understood process of positive/negative selection.
Because canonical T-cell development roughly consists
of 3 phases - 1) DLL-dependent T-lineage commitment,
2) DLL-independent beta-chain selection, and 3) DLL-
(in)dependent positive/negative selection, we investi-
gated whether T cell development could occur with
cells that already have received DLL-signaling and are
T/NK or completely T-lineage committed [22]. Unfortu-
nately, when T/NK-lineage committed cells were seeded
in skin-explants, most became NK-lineage committed
CD56+ cells (Figure 7), in the presence of additional IL-
15. Thymocyte-like cells were never detected. When IL-
15 was omitted, the viability and yield of the cultures
were reduced considerably, and most cells lost CD5 and
iCD3 expression (Figure 7), indicating that even in the
presence of IL-7 and Flt3-L, the keratinocyte/fibroblast
co-cultures were not able to maintain the T-lineage
committed status of cells. The few cells remaining also
displayed a CD56+ phenotype.
Discussion
Our results clearly demonstrate that the keratinocyte
differentiation procedure results either in fragile cells
that fail to adhere to any structure or plate, or cells that
do adhere but are outcompeted by fibroblasts within a
week. Furthermore, differentiated keratinocytes do not
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Figure 4 Keratinocytes have very low expression of DLL. (A): Next to FACS, Clark et al. [15] used immuno-fluorescence to demonstrate DLL
expression in immature keratinocyte-cultures. While the secondary antibody did not give any background staining (LL), there were occasional
H265-FITC positive cells (UR), but these always proved to be DAPI negative. In contrast to DLL, immature keratinocytes were reliably stained for
the Notch-ligand Jagged-1. (B) For PCR, 4 dilutions (5x-20x-80x-320x) were prepared from cDNA of mKer from 3 donors (A, B, and C), iKer from
donor C. Positive controls were prepared from murine TSt-4 cells constitutively expressing DLL-1 or DLL-4. At 35 cycles, DLL4-specific PCR
product was only detected in the 5x diluted samples, while mRNA encoding for Jagged-1 was easily amplified in 30 cycles.
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express detectable levels of DLL (protein nor RNA), and
therefore the T-lineage commitment observed by Clark
et al. [16] must be mediated by other factors. Jagged-1
may be responsible for steering development towards
the T-lineage of a limited fraction of CD34+ cells in
their co-culture system, because it is abundantly
expressed by keratinocytes. As stated in the results sec-
tion, certain T lineage committed stadia can complete
their development into DP and SP T cells independent
of Notch signaling [23].
However, even if T cells can be generated ex vivo
using the skin explants system, the question remains
whether they will be functional. Extra-thymic develop-
ment of T cells has been described for Oncostatin M
(OncM) transgenic mice, where LNs take over the func-
tion of the thymus [24]. Even though in OncM mice the
T cells appear to go through the same developmental
stages as regular thymocytes, they are less functional,
which may be the result of positive selection by other
hematopoietic cells instead of thymic epithelium [25].
This, however, remains to be elucidated for T cells
derived in any in vitro cell differentiation system.
The past decade knowledge-driven research has
revealed how T-lineage commitment can be induced in
HSC in vitro, using cell-lines transfected with huDLL
[8,26,27], or, to a certain extent, with recombinant
huDLL [28,29]. In contrast to mouse, differentiation of
human progenitors rarely get past the DP-stage of
thymocyte development, indicating it is difficult to push
them through the positive-negative selection process.
Interestingly, experiments with human T-progenitors
sorted as or arrested at a DN2-3-like stage, obtained
from either OP9-DLL or TSt-4-DLL - HSC co-cultures,
respectively, demonstrated that these cells were capable
of rapidly reconstituting the thymus of Rag2-/-gc
-/- mice,
where they completed their maturation [22,30]. Similar
experiments with murine T-progenitors have shown
that this approach considerably enhanced the generation
of functional T cells after HSC transplantation [31,32].
This approach will certainly be applicable to patients in
the near future, but still relies on the functional capacity
of the thymus, which is limited in older patients. In this
regard, more pragmatic research has resulted in several
viable approaches capable of improving thymic function
[33-35], which are now being tested in clinical trials
[36,37]. The solutions to both problems concerning T
cell reconstitution are expected to meet within the next
decade.
Conclusions
The results described by Clark et al. [15] are fascinating
and unique, but remain elusive. The results in the cur-
rent paper show that by following the published proce-
dure we could not obtain enough evidence to support
the basic skin cell co-culture conditions suggested to be
required for HSC differentiation towards mature T cells.
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Figure 5 Keratinocytes are out-competed by fibroblasts. (A) Matrix was stained for keratinocytes and fibroblasts using panCK and CD90,
respectively, six days after matrices were seeded at a 2:1 ratio. At this stage, matrices were carefully seeded with HSC. (B) After 4 weeks, matrices
were completely covered with CD90+ fibroblasts. HSC-derived cells could only be retrieved from the matrix following collagenase-dispase
treatment. Fibroblasts from all donors grew similarly.
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Recent advancements in the field of T cell lineage differ-
entiation and thymic rejuvenation will generate alterna-
tive procedures to reconstitute the T cell population
following HSC transplantation of man.
Methods
Cells
Abdominal or breast-skin was obtained from healthy
individuals (donor A-E) undergoing reconstructive
surgery, and processed within 24 hours. When required,
skin was kept in RPMI 1640 (Sigma-Aldrich Co., St.
Louis, MO, USA) supplemented with 100 IU/ml penicil-
lin, 100 μg/ml streptomycin (P/S) and 0,5 μg/ml fungi-
zone (all from Invitrogen Ltd., Paisley, UK) until
processing. After removal of subcutaneous fat (if applic-
able), skin was cut into small fragments and incubated
in phosphate buffered saline (PBS, Sigma) containing
2.4 U/mL Dispase II (Roche, Indianapolis, IL, USA)
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Figure 6 HSC expand, but do not differentiate in the skin-cell explants. HSC from donor V1 and V2 were seeded into skin-cell explants
from donor A and B. As controls, HSC were expanded for 1 week using a HSC expansion-mix, followed by maintenance with IL-7. For reasons
unknown, cell-numbers declined after 2-3 weeks in culture with skin-cell explants (not shown). The phenotype of the hematopoietic cells was
analyzed at various time-points after seeding, and the results of week 2 and 4 are depicted. Of markers associated with T-lineage commitment,
only CD7 was detected on 20-30%/60% of the cells in skin-cell explants/controls, and its expression-level increased from week 2 to 4.
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overnight at 4°C. Epidermis and dermis were separated
by tweezers.
To isolate keratinocytes, up to 20 epidermal sheets
were digested using 2 ml Trypsin/EDTA (Lonza, Ver-
viers, Belgium) for 5 minutes at 37°C. Following quick
neutralization by Trypsin Neutralizing solution (TNS,
Lonza), suspension was vortexed after which undigested
tissue was removed by subsequent filtration through 500
μm (Nedfilter, Almere, The Netherlands) and 70 μm
strainers (BD Biosciences, Erembodegem, Belgium).
Cells were spun down at 250 g for 10’, and resuspended
at approximately 2 × 105 cells/ml in Keratinocyte-SFM
medium containing 1% P/S, 0.39 mM CaCl2, bovine
pituitary extract (BPS) and epidermal growth factor
(EGF) according to the manufacturer’s descriptions (ker-
atinocyte medium, Invitrogen). Medium was changed
after 2-3 days, and islands appeared after 1-2 weeks.
Keratinocytes were passed to new flasks when islands
contained 30-50 cells; overall density of flasks was kept
at 30-40%. For experiments, keratinocytes used were
passaged 6x or less.
To isolate fibroblasts, 10-20 dermal fragments were
incubated at 37°C for 1 hour in DMEM/F12 (Invitrogen)
medium containing 2.5 mg/mL Trypsin, 0.2 U/mL
Liberase Bz3, and 0.2 mg/ml DNAse. Following neutrali-
zation with DMEM/F12 containing 15% fetal calf serum
(FCS, Greiner Bio-one, Solingen, Germany), cell-suspen-
sions were filtrated and spun down as described above.
Cells were seeded at 2 × 105 cells/ml in DMEM/F12
containing P/S, 15% FCS and 10 ng/ml EGF (fibroblast
medium). Fibroblast cultures were split when density
reached 100%. These cells were never split more than
8x before use in co-cultures.
Mobilized CD34+ stem cells
CD34+ cells were isolated from peripheral blood mono-
nuclear cells (PBMC) obtained from healthy volunteers
(V1-3) treated with G-CSF (Neupogen, Amgen Inc.,
Thousand Oaks, CA, USA) at MUMC+ (Maastricht, The
Netherlands). Isolation was performed with the Isolex
300i Magnetic cell selection system v2.5 (Baxter oncol-
ogy, Brussels, Belgium) using the Isolex stem cell reagent
kit (Miltenyi Biotec GmbH, Bergisch Gladbach,
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Figure 7 Skin-cell explants cannot maintain T-lineage committed cells. HSC from indicated donors were pre-differentiated on monolayers
of thymic stromal cells expressing huDLL-1 (see figure 2). After 4 weeks, 55-65% of the cells were CD5+CD7+ (see insert UL), and > 90% iCD3
+CD45RA+ (NS). 1 × 105 cells were seeded in skin-cell explants and cultured for 2 and 4 weeks. In the presence of IL15, the population expanded
10-15 ×. Already at 2 weeks, all cells had lost expression of CD5 and become CD56+ NK-lineage committed cells. The same phenotype was
observed when IL-15 was omitted, although overall expansion was strongly reduced to 1-1,5 ×.
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Germany) according to the manufacturer’s instructions.
The positive fraction containing > 94% CD34+ cells was
frozen at a concentration of 5 × 106 cells per ml per vial.
CD133+ cell preparations were obtained from Lonza.
Skin and CD34+ stem cells were obtained according to
protocols approved by, and guidelines stipulated by the
local medical ethical committee, and with consent from
the donors.
Maturation/differentiation of keratinocytes
Keratinocytes at 30-40% density were harvested using
Trypsin/EDTA and TNS (Lonza), quantified and seeded at
100% density in a 1:1 (vol/vol) mix of Keratinocyte-SFM
and DF-K medium. DF-K medium is a 1:1 (vol/vol) mix of
DMEM and Ham’s F12 containing P/S, 0.2 ng/ml EGF, 25
μg/ml BPS and 1.5 mM L-Glutamine (Invitrogen). Med-
ium was refreshed daily. This procedure only worked for
keratinocytes isolated from breast-skin and not for abdom-
inal skin.
The skin cell construct
Sterilized Statamatrix® (Cytomatrix, Australia) were coated
by incubation in PBS containing 100 μg/ml rat tail collagen
I (Roche) at 37°C, after which the coated matrices were
washed twice in PBS, and maintained in PBS until use.
Prior to use, matrices were transferred to non-tissue cul-
ture treated petridishes (Greiner), and PBS was aspirated.
Keratinocytes and fibroblasts were harvested, resuspended
in a 1:1 mixture of keratinocyte and fibroblast-medium
(ker-fib medium), and quantified. Subsequently, keratino-
cytes and fibroblasts were combined at 2 × 106 and 1 × 106
cells/ml, respectively, and 50-100 μl of this mix was
dripped onto a matrix. After 3 hours at 37°C, 5% CO2,
matrices were moved to 24-well plates and 2 ml ker-fib
medium was added. The skin cell constructs were cultured
for 6 days and medium was changed every other day.
Seeding of CD34+/CD133+ cells
After 6 days, medium was replaced by IMDM (Invitro-
gen) supplemented with 10% FCS (Greiner), 20 ng/ml
IL-7 and IL-15, and 100 ng/ml Flt3-L (all R & D sys-
tems, Abingdon, UK), then 1 × 104 CD34+ or CD133+
cells were dripped onto each matrix. Halve medium
change was done 3 times weekly.
TSt-4 Thymic stromal cell lines TSt-4 and TSt-4 trans-
duced with hDLL1 or hDLL4 were kindly supplied by
Dr. H. Kawamoto (RCAI-RIKEN, Yokohama, Japan) and
maintained in RPMI 1640 containing 5% fetal bovine
serum (FBS), 1% PS, 1 mM sodium pyruvate, 0.1 mM
MEM non essential amino acids (NEAA), and 5 × 10-5
M 2-mercaptoethanol (bME)(all from Invitrogen Ltd.,
Paisley, UK).
Flowcytometry
All antibodies, materials and equipment were obtained
from BD Biosciences unless stated otherwise, and were
used according to the manufacturer’s instructions. At
different time points, cells were analyzed using different
combinations of fluorescein isothiocyanate (FITC),
R-phycoerithrin (PE), peridinin chlorophyll-a protein
(PerCP)-, and allophycocyanin (APC) conjugated mono-
clonal antibodies (mAbs). The following antibodies
(clones) were used: CD1a (HI149), CD3 (UCHT1, SK7),
CD4 (SK3), CD5 (UCHT2, L17F12, MEM32 - Immuno-
tools, Friesoythe, Germany), CD7 (M-T701, 7F3 - San-
quin), CD8a (HIT8a, RPA T8), CD14 (M5E2), CD19
(HIB19), CD34 (8G12), CD38 (HB7), CD45 (2D1, HI30),
CD45RA (HI100), CD46 (E4.3), CD56 (B159), CD90
(AS02, Dianova, Hamburg, Germany), CD271 (C40-
1457), IFN-g (25723.11), NKG2A (131411, R&D Systems,
Minneapolis, MN, USA), NKp46 (9E2), TCRab (IP26 -
eBioscience), and TCRgδ (B1.1 - eBioscience). Unconju-
gated goat and rabbit antibodies used were DLL1 (#H20
and #H265), Nitric Oxide Synthase 2 (NOS2), IFN-g
Responsive Factor 1 (IRF1), Angiotensin-converting
enzyme (ACE) (all Santa Cruz Biotechnology, Santa
Cruz, CA, USA), for which the following conjugates were
used according to the manufacturer’s instructions: don-
key anti-goat FITC and donkey anti-rabbit FITC or APC
(all Jackson ImmunoResearch, West Grove, PA, USA).
7-amino-actinomycin D (7AAD) was used to differentiate
between viable and dead cells. For intracellular stainings,
cells were permeabilized using perm/wash. Cells were
analyzed on a FACSCalibur or FACScan with WinMDI
(Joe Trotter, http://facs.scripps.edu/) software.
Sorting
Prior to differentiation, CD34+ cell preparations were
depleted of CD38bright cells and contaminating T and
NK cells by cell-sorting using conjugated anti-CD3,
-CD4, -CD8, -CD38 and -CD56 antibodies. All CD34+
cell preparations had ≤ 0.05% contaminating mature
lymphoid cells. Sorting was performed on a FACSAria
(BD Biosciences) with FACSDiva software.
Immunofluorescence
Upon aspiration of media, monolayers or cells were
washed with PBS and fixed with cold methanol: acetone
(Merck) 1:1 for 10 minutes on ice. Following fixation,
preparations were washed 3 times with PBS at RT, with
each wash for 4 minutes on an orbital shaker. Blocking
was done with for 30’ with 1% normal donkey serum
(JIR) in PBS, after which preparations were washed
twice with PBS. The following primary antibodies were
used, each at the proper, predetermined dilution: CD46
(BD Biosciences), CD90 (Dianova), DLL1, Jagged-1
(both Santa Cruz), pan-cytokeratin (Acris, Hiddenhau-
sen, Germany), Keratin-10 (RKSE60), -14 (RCK107) and
-16 (LL025)(all MuBio, Maastricht, The Netherlands).
Preparations were incubated with primary antibodies for
1 hour at RT in the dark, after which they were washed
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5 times with PBS, followed by incubation with secondary
antibody for 1 hr at RT in the dark. Appropriate Texas
Red or FITC-labeled donkey anti-rabbit anti-goat, or
anti-mouse antibodies were obtained from Jackson
Immunoresearch. Following another washing procedure,
preparations were post-fixed for 15’ with 2% paraformal-
dehyde in PBS. Then, preparations were washed
twice, and covered with mounting medium containing
4’,6-diamidino-2-phenylindole (Vector Laboratories, Bur-
lingame, CA, USA). Preparations were analyzed using an
Axioplan 2 microscope and Axiovision software (Zeiss,
Jena, Germany).
PCR analysis
RNA was extracted from immature and matured kera-
tinocytes using Trizol according to the manufacturer’s
instructions (Invitrogen). Following quantification and
DNAse treatment, cDNA was synthesized using Super-
script III according to the manufacturer’s instructions
(Invitrogen). PCR was carried out in 20 μl reaction
volumes containing ≤ 80 ng or 40 ng RNA equivalent
from keratinocytes or TSt-4 cells, respectively. All PCR
components were used according to the manufacturer’s
instructions (iTaq, BioRad, Hercules, CA, USA) 100
nM of each primer (Eurogentec, Liege, Belgium). Pri-
mers used were (anneal temperature, optimal MgCl2):
Keratin-14 f-CACCTCTCCTCCTCCCAGTT r-CAT
CGTGCACATCCATGAC (63°C, 3 mM), DLL-1 f-CG
TCGAC TCCTTCAGTCTGC r-TTCTGTTGCGAG
GTCATCAG (60.5°C, 3 mM), DLL-4 f-TCCAAC
TGCCCTTCAATTTC r-ACTGCAGATGACCCGG
TAAG (57°C, 5 mM), and Jagged-1 f-CGGCCTCTG
AAGAACAGAAC r-CCTCAGAGGCTGAGTGTGTG
(62°C, 3 mM). All PCR products were validated by
TA-cloning and sequencing according to standard
procedures.
A signed response to: T cells fail to develop in
the human skin-cell explants system; an
inconvenient truth
Rachael A. Clare and Thomas S. Kupper
Department of Dermatology, Brigham and Women’s
Hospital, 221 Longwood Avenue, Boston, MA, USA
Response
The authors describe studies attempting to generate
human T cells in the cultured skin system we described
previously [38]. Their efforts failed to result in a robust
population of keratinocytes on the three-dimensional
matrix and they failed to observe T cell differentiation.
First and foremost, we agree that if there is not a viable
robust population of keratinocytes, T cell differentiation
will not occur. We have never observed successful
T cell generation in this system in without viable and
adherent keratinocytes that were at least as abundant as
fibroblasts. We believe that the failure of keratinocytes
to adhere and grow on the matrices in the authors’
hands is primarily a technical issue. Working with kera-
tinocytes can be difficult. These cells need to be pas-
saged at a very low density, under which they maintain
a basal cell-like phenotype. Once these cells reach a
high enough density or are exposed to other differentia-
tion signals, they can lose their ability adhere and prolif-
erate. As a brief technical note, we have found it is best
to plate cells onto the matrices while the keratinocytes
are in a basal cell-like phenotype and then allow them
to expand and differentiate in situ on the matrix. This
produces the desired population of mature keratinocytes
that are an absolute requirement for observing T cell
differentiation in the system. These are technical aspects
we would’ve been happy to share with the authors.
In the presence of viable keratinocytes, we do observe
T cell generation in the system. We absolutely stand by
our results, which are genuine. However, work over the
last several years has made us less enthusiastic about
this system for different reasons. First, the percentage of
viable T cells was never higher than 10% of the total
output of the matrices, even under the best conditions.
This was not enough to for clinical treatment of
patients. In order to scale the system up, we attempted
to transition to a two-dimensional culture system using
fibroblasts and keratinocytes. Under these conditions,
the skin cells grew well but T cell precursors only
matured to the double positive stage. Despite a great
deal of effort, we were unable to generate single positive
T cells in the two-dimensional system. Some aspect of
the three-dimensional system appears to be required.
We transduced human fibroblasts with human Delta-
like ligand 1 (DLL-1) in the hopes of eliminating the
need for human keratinocytes in this system, but this
was also not successful in producing mature, single posi-
tive T cells. The Statamatrix three-dimensional environ-
ment has actually been shown to support the survival
and multipotentcy of human hematopoietic precursor
cells, although the mechanism for this remains unclear
[39]. Although the need for three-dimensional environ-
ment is an interesting biologic question, we were
focused on generating T cells that could be used in
patients and so left this question for examination by our
colleagues working on T cell differentiation as their pri-
mary research focus.
Subsequent to the publication of our manuscript, we
also developed concerns about the specificity of the
H265 antibody. We generated human fibroblasts trans-
duced with human DLL-1 and found that cells expres-
sing DLL-1 by RT-PCR were not reliably detected by
flow cytometry with the H265 antibody, in agreement
with findings reported here by the authors. We
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discontinued using this antibody as a result. At the time
of our initial studies, this was the best DLL-1 antibody
available. However, the inadequacy of this commercially
available antibody does not change the fact that T cells
develop in the system.
We share the authors’ frustration that there is no
good system to generate naïve autologous T cells for
use in our patients after stem cell transplantation. In the
presence of a viable and robust population of keratino-
cytes, the explant system does support T cell differentia-
tion but we find that it supports the development of too
few T cells to be useful clinically. After several years
spent attempting to scale up the system for more signifi-
cant T cell production, we chose to move on to more
promising avenues of research. Once the signals that
support human T cell differentiation are more clearly
defined, it may be worth revisiting. However, we stand
by our results, which were genuine and reproducible.
One thing the authors and others may find of interest
are some recent findings in the field of peripheral tissue
immunity. We and other have found that T cells gener-
ated during a cutaneous immune response home to the
skin and remain there long term as a resident cell
population [40-42]. The normal skin surface of an adult
individual contains nearly 20 billion antigen-experienced
memory T cells, each of which is the product of a pre-
vious infectious challenge [43]. Similar resident popula-
tions of T cells exist in the gut and the lung [44]. We
would argue that these T cells, each of which is specific
for a known pathogen encountered in the past, have the
potential to be more valuable for restoring immunity in
patients after transplantation. Even if we could generate
millions of autologous naïve T cells, only a very small
fraction of these would be specific for pathogens actu-
ally encountered by our patients. A better approach
may be to transfer the established memory T cells from
the hematopoetic stem cell donor to the recipient. We
can expand 500,000 T cells from a 0.4cm2 skin biopsy
[45]. These cells are antigen-experienced memory T
cells with a substantial proliferative capacity and
impressive effector functions [43]. We would argue that
transferring these T cells, harvested and expanded from
a small skin biopsy taken at the time of stem cell har-
vest, could much more meaningful way to address the
immunosuppression our patients face after stem cell
transplantation.
In short, we agree with the authors that in the absence
of viable keratinocytes, there is no T cell development in
the system. We believe that the failure of keratinocytes to
populate the explant system in the authors hands is pri-
marily a technical issue, one we would have been happy
to help them address. However, even under the best con-
ditions, the system only produces a small number of T
cells. Several years of effort in scaling up the system or
adapting it to two-dimensional system have failed, at
least in our hands, to generate clinically significant num-
bers of T cells. Additional information on the process of
T cell development in humans is needed before we can
generate large number of naïve T cells in culture.
The authors and our team have the common goal of
improving immunity in our patients after hematopoetic
stem cell transplantation. It is unfortunate that the
authors, instead of contacting us for assistance in getting
keratinocytes to adhere and proliferate in their system,
chose to write a manuscript describing the fact that
when our system is inadequately reproduced, the results
are not the same. We would argue that this is not sur-
prising. However, the results we reported in our initial
manuscript are absolutely genuine. If the authors wish,
we would be happy to help them address these technical
issues, although we believe that expansion and transfer
of antigen experienced tissue resident T cells will prove
to be a better approach in the long run to restoring
patient immunity.
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